Home › Companies › VIR BIOTECHNOLOGY INC. › 2024-2025
Compiled from SEC Form N-PX filings and VIR BIOTECHNOLOGY INC.’s Form 8-K, filed May 29, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of May 29, 2025: 4 items on VIR BIOTECHNOLOGY INC.’s Form 8-K, filed May 29, 2025: 2 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore VIR BIOTECHNOLOGY INC. in the interactive database Compare manager voting policies
These tallies are VIR BIOTECHNOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey S. Hatfield | 93,985,116 | -- | -- | 10,933,739 | 12,050,291 | 90% | Elected | — |
| Elect Director: Saira Ramasastry | 98,467,755 | -- | -- | 6,451,100 | 12,050,291 | 94% | Elected | — |
| 2. Advisory Vote on Executive Compensation | 100,486,810 | 4,280,297 | 151,748 | -- | 12,050,291 | 96% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Public Accounting Firm | 116,311,775 | 162,660 | 494,711 | -- | 0 | 99.8% | Approved | — |
Source: VIR BIOTECHNOLOGY INC., Form 8-K, filed with the SEC on May 29, 2025 — read the filing on EDGAR.
Each item below shows how the 231 asset managers that disclosed a VIR BIOTECHNOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect the following two nominees for director to hold office until the 2028 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Jeffrey S. Hatfield
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Jeffrey S. Hatfield”): 93,985,116 for, 10,933,739 withheld, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the two persons listed below as Class III directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 34,021,573 for, 3,991,552 withheld, 18 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,395,937 | 0 | 18 | 4,773 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,076,919 | 0 | 0 | 3,048 | For |
| Charles Schwab | 1,294,724 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,016,012 | Withhold |
| Aberdeen | 0 | 0 | 0 | 693,192 | Withhold |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 352,870 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 256,512 | Withhold |
| Equitable | 143,072 | 0 | 0 | 98,230 | Mixed |
| PIMCO | 0 | 0 | 0 | 228,485 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 220,000 | Withhold |
| Prudential/PGIM | 201,717 | 0 | 0 | 12,130 | Mixed |
| Jackson National | 0 | 0 | 0 | 205,661 | Withhold |
| Invesco | 0 | 0 | 0 | 183,182 | Withhold |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 166,318 | Withhold |
| Global X | 162,750 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 117,626 | Withhold |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 0 | 0 | 101,968 | Withhold |
| Principal | 0 | 0 | 0 | 89,621 | Withhold |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 4 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the following two nominees for director to hold office until the 2028 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Saira Ramasastry
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Saira Ramasastry”): 98,467,755 for, 6,451,100 withheld, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the two persons listed below as Class III directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 35,340,977 for, 2,672,154 withheld, 12 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,395,943 | 0 | 12 | 4,773 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,079,967 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,294,724 | Withhold |
| Dimensional | 0 | 0 | 0 | 1,016,012 | Withhold |
| Aberdeen | 693,192 | 0 | 0 | 0 | For |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 352,870 | 0 | 0 | 0 | For |
| American Century | 256,512 | 0 | 0 | 0 | For |
| Equitable | 143,072 | 0 | 0 | 98,230 | Mixed |
| PIMCO | 228,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 220,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 201,717 | 0 | 0 | 12,130 | Mixed |
| Jackson National | 189,862 | 0 | 0 | 15,799 | Mixed |
| Invesco | 183,182 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 166,318 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 162,750 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 117,626 | 0 | 0 | 0 | For |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 101,968 | 0 | 0 | 0 | For |
| Principal | 89,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 11 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
VIR BIOTECHNOLOGY INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 100,486,810 for, 4,280,297 against — passed, per its Form 8-K filed May 29, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,393,382 | 7,345 | 0 | 0 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,075,564 | 4,403 | 0 | 0 | For |
| Charles Schwab | 1,294,724 | 0 | 0 | 0 | For |
| Dimensional | 1,016,012 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 693,192 | 0 | 0 | Against |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 0 | 352,870 | 0 | 0 | Against |
| American Century | 256,512 | 0 | 0 | 0 | For |
| Equitable | 143,072 | 98,230 | 0 | 0 | Mixed |
| PIMCO | 228,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 220,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 12,130 | 201,717 | 0 | 0 | Mixed |
| Jackson National | 205,661 | 0 | 0 | 0 | For |
| Invesco | 183,182 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 166,318 | 0 | 0 | 0 | For |
| Global X | 162,750 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 117,626 | 0 | 0 | 0 | For |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 101,968 | 0 | 0 | 0 | For |
| Principal | 89,621 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 36,625,620 for, 1,377,732 against, 9,590 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 16,684,041 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 12,916,663 | 0 | 0 | 0 | For |
| State Street | 4,919,656 | 37,474 | 0 | 0 | For |
| BlackRock | 3,875,631 | 21,322 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,294,031 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 2,248,249 | 0 | 0 | 0 | For |
| Fidelity | 2,216,094 | 0 | 0 | 0 | For |
| Charles Schwab | 1,374,506 | 0 | 0 | 0 | For |
| Artisan | 724,847 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 693,192 | 0 | 0 | Against |
| Clarius Group, LLC | 633,341 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 611,608 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 607,009 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 605,297 | 0 | 0 | 0 | For |
| Northern Trust | 592,924 | 829 | 0 | 0 | For |
| Woodline Partners LP | 466,737 | 0 | 0 | 0 | For |
| Renaissance | 466,118 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 459,337 | 0 | 0 | 0 | For |
| Vanguard | 457,134 | 0 | 0 | 0 | For |
| JPMorgan | 438,996 | 0 | 0 | 0 | For |
| Nuveen | 0 | 356,275 | 0 | 0 | Against |
| Citadel | 339,475 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 300,403 | 0 | 0 | Against |
| Corient Private Wealth LLC | 279,998 | 0 | 0 | 0 | For |
| Invesco | 267,470 | 0 | 0 | 0 | For |
Institutional-manager reports, all 192 managers: 56,778,355 for, 2,847,627 against. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
VIR BIOTECHNOLOGY INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 116,311,775 for, 162,660 against — passed, per its Form 8-K filed May 29, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 38,003,426 for, 127 against, 9,590 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,400,728 | 0 | 0 | 0 | For |
| BlackRock | 10,408,325 | 0 | 0 | 0 | For |
| Fidelity | 4,301,200 | 0 | 0 | 0 | For |
| State Street | 3,079,840 | 127 | 0 | 0 | For |
| Charles Schwab | 1,294,724 | 0 | 0 | 0 | For |
| Dimensional | 1,016,012 | 0 | 0 | 0 | For |
| Aberdeen | 693,192 | 0 | 0 | 0 | For |
| Artisan | 548,541 | 0 | 0 | 0 | For |
| JPMorgan | 380,390 | 0 | 0 | 0 | For |
| TIAA | 352,870 | 0 | 0 | 0 | For |
| American Century | 256,512 | 0 | 0 | 0 | For |
| Equitable | 241,302 | 0 | 0 | 0 | For |
| PIMCO | 228,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 220,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 213,847 | 0 | 0 | 0 | For |
| Jackson National | 205,661 | 0 | 0 | 0 | For |
| Invesco | 183,182 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 182,507 | 0 | 0 | 0 | For |
| Victory Capital | 166,318 | 0 | 0 | 0 | For |
| Global X | 162,750 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,027 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 117,626 | 0 | 0 | 0 | For |
| Putnam | 105,983 | 0 | 0 | 0 | For |
| BNY Mellon | 101,968 | 0 | 0 | 0 | For |
| Principal | 89,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 138,063,698 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.98% |
| 2 | BlackRock | 7.54% |
| 3 | Fidelity | 3.12% |
| 4 | State Street | 2.23% |
| 5 | Charles Schwab | 0.94% |
| 6 | Dimensional | 0.74% |
| 7 | Aberdeen | 0.50% |
| 8 | Artisan | 0.40% |
| 9 | JPMorgan | 0.28% |
| 10 | TIAA | 0.26% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 12.08% |
| 2 | ARCH Venture Management, LLC | 9.36% |
| 3 | State Street | 3.59% |
| 4 | BlackRock | 2.82% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.66% |
| 6 | ORBIMED ADVISORS LLC | 1.63% |
| 7 | Fidelity | 1.61% |
| 8 | Charles Schwab | 1.00% |
| 9 | Artisan | 0.53% |
| 10 | Aberdeen | 0.50% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| SVF Endurance (Cayman) Ltd. | 12.08% | DEF14A |
| BlackRock | 11.98% | 13F |
| Robert Nelsen | 9.83% | DEF14A |
| Entities affiliated with ARCH Venture Partners, L.P. | 9.36% | DEF14A |
| Vanguard Group | 9.28% | 13F |
| SB Investment Advisers (UK) Limited | 7.93% | 13G |
| Glaxo Group Limited | 6.19% | DEF14A |
| State Street | 4.15% | 13F |
| George Scangos, Ph.D. | 3.44% | DEF14A |
| Dimensional Fund Advisors | 1.94% | 13F |
Percentages above are of 138,063,698 shares outstanding, as reported by VIR BIOTECHNOLOGY INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIR BIOTECHNOLOGY INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At VIR BIOTECHNOLOGY INC.'s shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 231 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,185 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — VIR BIOTECHNOLOGY INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: VIR BIOTECHNOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2025.
VIR BIOTECHNOLOGY INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.